Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
Fidaxomicin is sporicidal and may be associated with a reduced time to resolution of diarrhoea when used to treat patients with Clostridium difficile infection (CDI). This study investigated whether fidaxomicin for treatment of all patients with CDI reduced C. difficile environmental contamination. Surfaces in the rooms of 66 hospitalized patients treated with metronidazole and/or vancomycin and 68 hospitalized patients treated with fidaxomicin were sampled. Patients treated with fidaxomicin were less likely to contaminate their environment (25/68, 36.8%) than patients treated with metronidazole and/or vancomycin (38/66 57.6%) (P = 0.02). Treatment with fidaxomicin was associated with reduced environmental contamination with C. difficile.
Centre for Clinical Infection and Diagnostics Research, King's College, London and Guy's & St Thomas' NHS Foundation Trust, London, UK.
J S
JS
Biswas
Centre for Clinical Infection and Diagnostics Research, King's College, London and Guy's & St Thomas' NHS Foundation Trust, London, UK.
A
A
Patel
Centre for Clinical Infection and Diagnostics Research, King's College, London and Guy's & St Thomas' NHS Foundation Trust, London, UK.
J A
JA
Otter
Centre for Clinical Infection and Diagnostics Research, King's College, London and Guy's & St Thomas' NHS Foundation Trust, London, UK.
P
P
Wade
Centre for Clinical Infection and Diagnostics Research, King's College, London and Guy's & St Thomas' NHS Foundation Trust, London, UK.
W
W
Newsholme
London School of Hygiene and Tropical Medicine, London, UK; Public Health England, Colindale, London, UK.
E
E
van Kleef
Centre for Clinical Infection and Diagnostics Research, King's College, London and Guy's & St Thomas' NHS Foundation Trust, London, UK. Electronic address: simon.goldenberg@gstt.nhs.uk.
S D
SD
Goldenberg
D000328:Adult; D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000187:drug effects / Q000302:isolation & purification*; D003015:Clostridium Infections / Q000188:drug therapy* / Q000382:microbiology*; D003428:Cross Infection / Q000382:microbiology / Q000517:prevention & control; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology*; D004783:Environmental Microbiology; D005260:Female; D000077732:Fidaxomicin; D006760:Hospitalization; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D008795:Metronidazole; D014640:Vancomycin; D000077732:Fidaxomicin
Clostridium difficile; Contamination; Environment; Fidaxomicin